三鑫医疗：实控人之一致行动人彭九莲拟减持不超过230万股

Core Viewpoint - The announcement from Sanxin Medical indicates that several key stakeholders, including the controlling shareholder and executives, plan to reduce their shareholdings in the company within the next three months, which may impact investor sentiment and stock performance [2][3]. Shareholding Reduction Plans - Controlling shareholder Peng Jiulian intends to reduce her holdings by up to 2.304 million shares, representing 0.4404% of the total share capital [2]. - CEO Mao Zhiping plans to sell up to 740,000 shares, accounting for 0.1424% of the total share capital [2]. - Director Le Zhenrong aims to reduce his holdings by up to 390,000 shares, which is 0.0753% of the total share capital [2]. - Vice President Liu Ming will sell up to 170,000 shares, representing 0.032% of the total share capital [3]. - Vice President Wang Ganying plans to reduce his holdings by up to 230,000 shares, accounting for 0.0436% of the total share capital [3]. - Vice President Leng Lingli intends to sell up to 130,000 shares, which is 0.0251% of the total share capital [3]. - Vice President Liu Bingrong plans to reduce his holdings by up to 130,000 shares, representing 0.025% of the total share capital [3]. Revenue Composition - For the first half of 2025, Sanxin Medical's revenue composition shows that the medical device industry accounts for 99.78% of total revenue, while other businesses contribute 0.22% [4].